Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : coug's news and views -- Ignore unavailable to you. Want to Upgrade?

To: coug who wrote (5)	7/1/2004 4:16:11 PM
From: coug	Read Replies (1) \| Respond to of 3961

Also bought at EOD a Mad Cow lotto ticket.. GENETHERA.. GTHA...We will see... Be careful Boys n Girls, It's bottom fishing.. stockcharts.com[w,a]dacayyay[dd][pb50!b200!f][vc60][ WEB PAGE genethera.net Little more info from this site cashcowmag.com <<<<<<<<<<<<<<<<<<<<<<<<< Shares Out 2,998,000 Float 643,000 Printable one page .PDF GTHA.pdf Website GeneThera.com Press Releases • GeneThera Launches New R & D Services Division Thu March 7 - Market Wire • Reminder - Media Advisory: VasoActive -- 2004's Hottest IPO Leads Off Equities' Emerging Growth Stock Day XI Conference on February 27th Fri, Feb 27 - Market Wire • Media Advisory: VasoActive -- 2004's Hottest IPO Leads Off Equities' Emerging Growth Stock Day XI Conference on February 27th Wed, Feb 25 - Market Wire More Headlines for GTHA.OB... "Through a single blood sample, GeneThera can detect and treat a variety of diseases in live animals. The capability of detecting infection in LIVE animals is unique to GeneThera, as it does not exist in the industry today." GENETHERA, INC. (OTCBB:GTHA) operates a recognized molecular biotech laboratory in Wheat Ridge, Colorado. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the healthcare industry. The Company was formed to realize the commercial potential of molecular diagnostic assays using Roche’s PCR technology to detect the presence of infectious disease from the blood of animals, particularly live animals. This platform enables GeneThera to offer tests that are presently not available from any other technology. Future plans include all infectious disease potentially affecting domesticated livestock as well as wildlife intended for human consumption with priority being given to MAD COW and Foot & Mouth diseases in cattle. To date, GeneThera has successfully developed the ability to detect Chronic Wasting Disease, (CWD) a disease affecting elk and deer in North America, and E.Coli O157:H7 and Johnne's Disease, both of which are associated with cattle. Johnne’s disease is a contagious, chronic, and usually fatal infection that primarily affects the small intestines of ruminants. Some reports state that as many as 20% of all cattle in the U.S. are infected with this disease which may also be linked to Crohne’s disease in humans. No one else has a single animal test for this disease. On July 19, 2002, 19 million pounds of beef at the ConAgra plant in Greeley, Colorado was found to be infected with E.Coli O157:H7. This beef was recalled from retail stores in 21 states after at least 19 people had become infected with the E. Coli bacteria. GeneThera aims to decrease these statistics. A test that detects the presence of MAD COW disease in live animals is also being developed. It will identify a genetic marker that appears to be uniquely targeted when the infectious prion proteins are present. This test can identify the specific animal that is likely infected without classifying the entire herd as infected, thereby preventing wholesale slaughter without proper validation. Contact: Founded in 1995 by Dr. Tony Milici, GeneThera today is a fully reporting company to the Security and Exchange Commission and trades on the electronic NASDAQ Over The Counter Bulletin Board under GTHA trading symbol. Location The Company is located at: 3930 Youngfield Street Wheat Ridge, CO 80033 303.463.6371 phone The Regency Group For investor relations inquiries, please contact the Regency Group at the following: 303.771.7300 phone 303.771.7310 fax www.regency-financial.com regencyfinancial@regency-financial.com _______________________________________________________ SAFE HARBOR PROVISION Except for historical information contained herein, the statements in this company description that are forward-looking statements are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the company's actual results in future periods to differ materially from forecasted results. Such risks and uncertainties include, but are not limited to, market conditions, competitive factors, the ability to successfully complete additional financings and other risks.